The Latest Breaking News on Pharma

Biogen has agreed to pay $900 million to resolve allegations that it violated federal law by paying kickbacks to doctors in the form of speakers and consulting fees to persuade them to prescribe its multiple sclerosis drugs

The biotech industry witnessed solid growth during the pandemic. However, that seems to be fading away amid the receding pandemic and growing recession concerns. So, it could be wise to avoid biotech stocks Ginkgo Bioworks Holdings (DNA), GeoVax Labs (GOVX), and Aditxt (ADTX), given their bleak fundamentals. Read on….

Record-high inflation, the Federal Reserve's hawkish stance, and growing recession fears have increased market volatility. Nevertheless, despite the unsettling macroenvironment, few stocks have delivered stable returns and could continue to beat the market based on their solid growth attributes. AbbVie Inc. (ABBV), J. Jill Inc. (JILL), and Bassett Furniture Industries…

The new chief at the Food and Drug Administration's tobacco center has inherited a raft of problems

Pfizer is asking the Food and Drug Administration to expand use of its updated COVID-19 booster shot to children ages 5 to 11

Carvedilol could be the poster child for how to lower drug prices. Since 2007, more than 20 million patients with cardiovascular conditions have enjoyed generic versions of the popular beta-blocker, which cost 2 cents a dose compared with $4.81 for the brand-name product. Patents on the drug Coreg, dating back…

Many pharmacies and physicians are forced to deny patients access to drugs, such as methotrexate, that can be used to help induce an abortion

BOSTON — Eight years after the ALS Ice Bucket Challenge went viral across social media and raised hundreds of millions of dollars for research, a Cambridge company is on the brink of a major breakthrough for ALS patients.

As demand for menopause drugs soars, we trace the oestrogen production line from Chinese soya bean fields to European pharmacy shelves

The application for children ages 6 months to under 6 years is expected to be completed later this year.

As billions of dollars in opioid lawsuit settlements are starting to flow to governments, families and advocates impacted by the opioid crisis are pushing for a meaningful say in how the money will be used